In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against other worst ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PTC Therapeutics (PTCT – Research Report) and ...

Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

Investment analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research note issued on Monday, March 24th. HC Wainwright analyst R.

In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against other worst high-risk high-reward growth stocks to buy. On March 14, Tom Lee ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

Yann Mazabraud, the EVP of $RYTM, sold 55,803 shares of the company on 03-14-2025 for an estimated $2,886,226. We received data on the trade from a recent SEC filing ...

Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...

Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.

US biotech Rhythm Pharmaceuticals (Nasdaq: RYTM) has reacquired the rights to its obesity treatment Imcivree (setmelanotide) ...